Results 201 to 210 of about 27,891 (313)

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK. [PDF]

Endocr Connect
Van Sloten T, Hageman SHJ, Westerink J, Capucci S, Diogo da Rocha Fernandes J, Holloway S, Pijper A, Tikhonovsky N, Emerson S, Lincoff AM, Plutzky J, Lingvay I.   +11 more
europepmc   +1 more source

Association of semaglutide with risk of suicidal ideation in a real-world cohort

Nature Medicine
William Wang, Nora D. Volkow, Nathan A. Berger, P. Davis, D. Kaelber, R. Xu   +5 more
semanticscholar   +1 more source

Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia. [PDF]

Healthcare (Basel)
Dayel FFB, Alanazi RJ, Alenazi MA, Alkhalifah S, Dayel DFB, Mawkili W, Alwhaibi A.   +6 more
europepmc   +1 more source

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon‐like peptide‐1 receptor agonist [GLP‐1 RA]) versus fixed‐ratio combination (FRC) therapy (basal insulin plus a GLP‐1 RA) among individuals with type 2 diabetes (T2D) in Japan.
Takeshi Miyatsuka, James Brash, Eleanor Davies, Elisabeth de Laguiche, Dorte Vistisen, Can Yin, Atif Adam   +6 more
wiley   +1 more source

Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study. [PDF]

Diabetes Metab Syndr Obes
Cetiner S.
europepmc   +1 more source

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Oral semaglutide absorption is subject to inter‐individual variability. We investigated whether estimated individual exposure (eCavg) provides predictive information beyond the prescribed dose in a real‐world cohort of patients with type 2 diabetes (T2D).
Gian Paolo Fadini, Mario Luca Morieri, Carlotta Boscaro, Benedetta Maria Bonora, Andrea Cignarella   +4 more
wiley   +1 more source

A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity. [PDF]

Healthcare (Basel)
Lee AH, Holmes-Walker DJ.
europepmc   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT‐J Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the impact of tirzepatide on health‐related quality of life (HR‐QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT‐J trial. Materials and Methods Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle ...
Hiroaki Masuzaki, Hirotaka Nagashima, Tomotaka Shingaki, Tomonori Oura, Ichiro Tatsuno   +4 more
wiley   +1 more source